Daniel Cui Zhou
Overview
Explore the profile of Daniel Cui Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E, et al.
Nat Cancer
. 2024 Oct;
5(11):1713-1736.
PMID: 39478117
Breast cancer (BC) is defined by distinct molecular subtypes with different cells of origin. The transcriptional networks that characterize the subtype-specific tumor-normal lineages are not established. In this work, we...
2.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E, et al.
bioRxiv
. 2023 Nov;
PMID: 37961519
Breast cancer is a heterogeneous disease, and treatment is guided by biomarker profiles representing distinct molecular subtypes. Breast cancer arises from the breast ductal epithelium, and experimental data suggests breast...
3.
Li Y, Porta-Pardo E, Tokheim C, Bailey M, Yaron T, Stathias V, et al.
Cell
. 2023 Aug;
186(18):3921-3944.e25.
PMID: 37582357
Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-cancer analysis uncovers insights into the impacts of...
4.
Li Y, Dou Y, Veiga Leprevost F, Geffen Y, Calinawan A, Aguet F, et al.
Cancer Cell
. 2023 Aug;
41(8):1397-1406.
PMID: 37582339
The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics datasets connecting genomic aberrations to cancer phenotypes. To facilitate pan-cancer investigations,...
5.
Wu Y, Terekhanova N, Caravan W, Naser Al Deen N, Lal P, Chen S, et al.
Nat Commun
. 2023 May;
14(1):2817.
PMID: 37198186
No abstract available.
6.
Wu Y, Terekhanova N, Caravan W, Naser Al Deen N, Lal P, Chen S, et al.
Nat Commun
. 2023 Mar;
14(1):1681.
PMID: 36973268
Identifying tumor-cell-specific markers and elucidating their epigenetic regulation and spatial heterogeneity provides mechanistic insights into cancer etiology. Here, we perform snRNA-seq and snATAC-seq in 34 and 28 human clear cell...
7.
Zuo C, Baer J, Knolhoff B, Belle J, Liu X, de la Lastra A, et al.
J Exp Med
. 2023 Mar;
220(6).
PMID: 36951731
Tumor-associated macrophages (TAMs) are abundant in pancreatic ductal adenocarcinomas (PDACs). While TAMs are known to proliferate in cancer tissues, the impact of this on macrophage phenotype and disease progression is...
8.
Yao L, Wang J, Jayasinghe R, ONeal J, Tsai C, Rettig M, et al.
Cancer Res
. 2023 Feb;
83(8):1214-1233.
PMID: 36779841
Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
9.
Li Q, Hu Y, Chen L, Schnaubelt M, Zhou D, Li Y, et al.
Clin Proteomics
. 2022 Oct;
19(1):36.
PMID: 36266629
Background: The identification of differentially expressed tumor-associated proteins and genomic alterations driving neoplasia is critical in the development of clinical assays to detect cancers and forms the foundation for understanding...
10.
Kossenkov A, Milcarek A, Notta F, Jang G, Wilson J, Gallinger S, et al.
PLoS One
. 2022 Oct;
17(10):e0273520.
PMID: 36223343
Changes in metabolism are a hallmark of cancer, but molecular signatures of altered bioenergetics to aid in clinical decision-making do not currently exist. We recently identified a group of human...